8-K: Amprius Announces CEO Transition, Stepien to Lead

Amprius Technologies, Inc. announced Dr. Kang Sun will step down as CEO, transitioning to Executive Advisor, while President Tom Stepien will assume the CEO role effective January 1, 2026.

Summary

• Dr. Kang Sun will transition from Chief Executive Officer to Executive Advisor, effective January 1, 2026, and will remain a member of the Board of Directors.
• Mr. Tom Stepien, currently President, has been appointed Chief Executive Officer, effective January 1, 2026.
• Dr. Sun's decision to step down is not due to any disagreement regarding company operations, policies, or practices.
• Mr. Stepien will receive an annual base salary of $633,000 and will be eligible for an annual cash bonus with a target of 100% of his base salary.
• Mr. Stepien was granted 200,000 restricted stock units (RSUs) on December 19, 2025, vesting over approximately four years.
• As Executive Advisor, Dr. Sun will receive an annual salary of $633,000 and remain eligible to vest in outstanding equity awards.

Sentiment

Score: 7

Explanation: The transition appears well-managed and amicable, with the outgoing CEO remaining involved as an advisor and board member, and the incoming CEO bringing relevant industry experience. This suggests stability and a planned succession, which is generally positive, though any CEO change carries some inherent uncertainty.

Positives

• Continuity of leadership is maintained with Dr. Kang Sun remaining on the Board and transitioning to an Executive Advisor role.
• The new CEO, Tom Stepien, brings extensive experience in battery technology and industrial technologies, having served as CEO of South 8 Technologies and co-founded Primus Power.
• The transition is explicitly stated not to be a result of any disagreement, suggesting a planned and amicable succession.

Negatives

• Any CEO transition, even if planned, can introduce a degree of uncertainty regarding future strategic direction and operational execution.
• Dr. Sun, a key figure in the company's leadership, is stepping back from day-to-day operational responsibilities.

Risks

• Leadership Transition Risk: Any change in top leadership carries inherent risks related to strategic direction, operational execution, and employee morale, despite the stated amicable nature of the transition.
• Integration Risk: The new CEO, while experienced, will need to fully integrate into the CEO role and ensure a smooth transition of responsibilities and strategic alignment.

Future Outlook

The appointment of Mr. Tom Stepien as the new CEO, with his background in battery and industrial technologies, suggests a continued focus on strategic growth and innovation within the company's core business. Dr. Sun's transition to Executive Advisor indicates ongoing strategic input from the former CEO, aiming for a stable leadership transition.

Management Comments

• Dr. Sun's decision to step down is not the result of any disagreement regarding any matter relating to the Company's operations, policies or practices.

Industry Context

This leadership transition occurs within the rapidly evolving battery technology sector, where innovation, strategic execution, and experienced leadership are critical. The appointment of a CEO with a strong background in lithium-ion battery electrolytes and long-duration storage suggests Amprius is positioning itself to capitalize on advancements and market demand in high-performance battery solutions.

Management Changes

Stakeholder Impact

• Shareholders: Potential for stability and continued strategic direction with an experienced new CEO and the former CEO remaining as an advisor.
• Employees: A planned leadership transition can provide clarity and minimize disruption, especially with an internal promotion.
• Customers/Suppliers: Likely minimal immediate impact as the company maintains leadership continuity and strategic focus.

Next Steps

• Dr. Kang Sun will assume the role of Executive Advisor on January 1, 2026.
• Mr. Tom Stepien will officially commence his role as Chief Executive Officer on January 1, 2026.
• The Company will file the complete text of Dr. Sun's amended and restated employment agreement as an exhibit to its Annual Report on Form 10-K for the fiscal period ending December 31, 2025.

Key Dates

Recommendation

The leadership transition appears well-managed and amicable, with Dr. Sun remaining as an Executive Advisor and Board member, and Mr. Stepien bringing relevant industry experience. This suggests continuity and a planned succession, which mitigates immediate concerns. However, any CEO change introduces a degree of uncertainty regarding future strategic execution. Investors should hold to observe the new CEO's strategic direction and performance before making further investment decisions.

Keywords

Amprius Technologies, CEO change, leadership transition, Tom Stepien, Kang Sun, battery technology, executive appointment, corporate governance, restricted stock units, AMPX